文献速递其他结缔组织病

抗磷脂酰丝氨酸/凝血酶原抗体与凝集素补体途径在抗磷脂抗体相关早产中的作用

The Role of Anti-Phosphatidylserine/Prothrombin Antibodies and the Lectin Complement Pathway in Anti-Phospholipid Antibody-Associated Preterm Delivery.
PubMed 文献 · Arthritis Rheumatol · 2026-07-13

该前瞻性研究纳入60名孕妇(33例aPL阳性,27例aPL阴性),探讨分类/非分类APS实验室标准及补体激活标志物对妊娠并发症尤其是早产的预后价值。结果显示,早产妇女抗PS/PT IgG/IgM滴度在几乎所有时间点显著更高,且aPL阳性早产者凝集素途径活性降低,与抗PS/PT滴度及分娩孕周相关。

要点

  • 早产妇女抗PS/PT IgG/IgM滴度在几乎所有时间点显著高于非早产者。
  • aPL阳性早产者凝集素途径活性低于非早产者,与aPL阴性早产者差异显著。
  • 早孕期凝集素途径活性与抗PS/PT滴度相关,且均与分娩孕周相关。

核心结论

  • aPL阳性孕妇早孕期抗PS/PT IgG/IgM滴度升高和凝集素途径活性降低可能作为早产的早期预后工具。

研究设计与样本

  • 前瞻性观察60名孕妇,其中33例aPL阳性(20例APS和13例aPL携带者),27例aPL阴性(5例SLE、11例RA和11例UCTD),检测231份标本。

主要发现

  • aPL阳性妇女早产发生率为21%,aPL阴性妇女为15%。
  • 早产 versus 非早产妇女抗PS/PT IgG/IgM滴度在几乎所有时间点显著更高(P < 0.05)。
  • aPL阳性早产者凝集素途径活性低于非早产者,与aPL阴性早产患者相比差异有统计学意义(P < 0.05)。
  • 早孕期凝集素途径活性与抗PS/PT IgG/IgM滴度显著相关(P < 0.05),且均与分娩孕周显著相关(P < 0.05)。

关键数值与推荐

  • 抗PS/PT IgG/IgM滴度在早产 versus 非早产妇女中差异显著(P < 0.05)。
  • aPL阳性早产者凝集素途径活性与aPL阴性早产者差异显著(P < 0.05)。
  • 早孕期凝集素途径活性与抗PS/PT IgG/IgM滴度相关(P < 0.05),与分娩孕周相关(P < 0.05)。

临床怎么用

  • 对于aPL阳性孕妇,早孕期可检测抗PS/PT IgG/IgM滴度和凝集素途径活性以评估早产风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antiphospholipid antibodies (aPL) may directly affect placentation and trigger local complement-mediated inflammation/thrombosis. Obstetric complications in the antiphospholipid syndrome (APS) are still frequent despite therapy/close monitoring, and the identification of new risk biomarkers is an unmet need. We aimed to prospectively investigate the prognostic value of classification/nonclassification laboratory APS criteria and markers of complement activation for pregnancy complications, in particular preterm delivery (PTD). METHODS: We observed 60 women prospectively during pregnancy and postpartum: 33 aPL-positive (20 APS and 13 aPL-carriers) and 27 aPL-negative (5 systemic lupus erythematosus, 11 rheumatoid arthritis and 11 undifferentiated connective tissue diseases). aPL criteria tests, anti-phosphatidylserine/prothrombin (anti-PS/PT) IgG/IgM and anti-β2glycoprotein I-Domain I IgG, complement products (C3, C4, C3a, C5a, sC5b-9, MBL) and complement pathway activity (classical pathway [CP], alternative pathway [AP], and lectin pathway [LP]) were measured in 231 available specimens. RESULTS: PTD was experienced in 21% of aPL-positive and 15% of aPL-negative women. Anti-PS/PT IgG/IgM titers were significantly higher in PTD versus non-PTD women (P < 0.05) at almost all time points. At variance with CP and AP, LP activity in aPL-positive PTD was lower than in non-PTD, reaching a statistically significant difference compared with aPL-negative PTD patients (P < 0.05). Moreover, LP activity significantly correlated with anti-PS/PT IgG/IgM titers, both measured in the first trimester (P < 0.05), and all of them significantly correlated with the week of gestation at delivery (P < 0.05). CONCLUSION: The reduced LP activity and the higher anti-PS/PT IgG/IgM titers in PTD aPL-positive women during the first trimester suggest their use as early prognostic tools for PTD in aPL-positive pregnant women.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Da Via A, Borghi MO, Trespidi L, et al. The Role of Anti-Phosphatidylserine/Prothrombin Antibodies and the Lectin Complement Pathway in Anti-Phospholipid Antibody-Associated Preterm Delivery. Arthritis Rheumatol. 2026. PMID: 42439305. doi:10.1002/art.70273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。